Aim: Cisatracurium is an intermediate duration non-depolarising neuromuscular blocking drug and is devoid of histamine release. However, 2× ED95 dose of cisatracurium does not provide satisfactory intubating condition. The objective of this study was to evaluate and compare onset of action, hemodynamic effects and any adverse effects for different doses of cisatracurium. Method: The study designed as randomized controlled clinical trial to compare between atracurium (2×ED(95) and different doses of cisatracurium (2×ED(95), 3×ED(95) regarding onset time, duration of action, condition of intubation, hemodynamic effects, and sings of histamine release clinically. Sixty four patients were randomly assigned to one of three groups, the first group (group 1) received 2×ED(95) dose of atracurium, group 2 received 2×ED(95) dose of cisatracurium, group 3 received 4×ED(95) dose of cisatracurium, while group 4 received 6×ED(95) dose of cisatracurium. The Datex relaxograph (Type NMT-100-23-01, S/N: 37541) for neuromuscular monitoring was used. Results: Onset time was found to be significantly lower with 2×ED(95) dose of atracurium than with the same dose of cisatracurium. At the same time, higher doses of cisatracurium (4×ED(95) and 6×ED(95)) showed onset time and longer duration of action that was significantly lower than with atracurium and with lower dose of cisatracurium (2×ED(95)). Conclusion: The same dose (2×ED(95) dose) atracurium is more effective neuromuscular blocking agent than cisatracurium, while higher doses of cisatracurium 4×ED(95) and 6×ED(95) provide more effective, more rapid neuromuscular blocking with longer duration of action, stable hemodynamic status, and no associated signs of histamine release clinically.